We are live on ! Find out more
EYEGW

Eyegate Pharmaceuticals, Inc. Warrants
EYEGW

Delisted

EYEGW was delisted on the 5th of August, 2020.

Back to rankings

5 hedge funds and large institutions have $304K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2016 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 5 → 5 (0)

22% less capital invested

Capital invested by funds: $390K → $304K (-$86K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$75.3K
2
ICM
Ionic Capital Management
New York
-$3.81K
Name Holding Trade Value Shares
Change 		Change in
Stake
ICM
1
Ionic Capital Management
New York
$115K -$3.81K -5,500 -3%
AIC
2
AWM Investment Company
New York
$103K – – –
SM
3
Sabby Management
Florida
$49K -$75.3K -108,757 -62%
BA
4
BlackRock Advisors
Delaware
$35K – – –
VIA
5
Vantage Investment Advisors
Pennsylvania
$2K – – –

EYEGW Hedge Fund Activity: Q1 2016 in Review

5 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q1 2016, worth a combined $304K — down 22% from $390K a quarter earlier.

Fund positioning in EYEGW was balanced in Q1 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.

The largest seller was Sabby Management, cutting an estimated $75.3K.

  • 5 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $304K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q1 2016, down 22% quarter-over-quarter.
  • 0 funds opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q1 2016 and 0 closed out.
  • The largest Eyegate Pharmaceuticals, Inc. Warrants seller in Q1 2016 was Sabby Management, an estimated $75.3K sold.

Based on aggregated 13F filings for Q1 2016.